Outcomes | № of participants (studies) Follow-up | Certainty of the evidence (GRADE) | Relative effect (95% CI) | Anticipated absolute effects | |
---|---|---|---|---|---|
Risk with Non-adherence to CG* | Risk difference with adherence to CG | ||||
Overall survival assessed with: adjusted hazard ratio follow up: median 60 monthsa | ⨁⨁⨁◯ MODERATE a,b | HR 0.67 (0.59 to 0.76) [death] | 431 per 1.000 c | 138 more per 1.000 (96 more to 178) | |
Disease free survival assessed with: adjusted hazard ratio follow up: median 60 monthsa | ⨁⨁◯◯ LOW a,b,d | HR 0.35 (0.15 to 0.82) [recurrence] | 370 per 1.000 e | 336 more per 1.000 (73 moreto 491 more) | |
Treatment costsf | (1 observational study) [39] | ⨁⨁◯◯ LOW f, | Higher costs for treatment concordant to CG. | ||
Follow-up costsf | (1 observational study) [38] | ⨁⨁◯◯ LOW f, | Non-CGs adherent follow-up was 2.2 to 3.6 times more expensive than the compliant one [5, 7]. |